## CORRECTION Open Access



## Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis

Xiao-Yong Huang<sup>1†</sup>, Peng-Fei Zhang<sup>1†</sup>, Chuan-Yuan Wei<sup>1†</sup>, Rui Peng<sup>1†</sup>, Jia-Cheng Lu<sup>1†</sup>, Chao Gao<sup>1</sup>, Jia-Bing Cai<sup>1</sup>, Xuan Yang<sup>1</sup>, Jia Fan<sup>1,2</sup>, Ai-Wu Ke<sup>1,2\*</sup>, Jian Zhou<sup>1,2,3,4\*</sup> and Guo-Ming Shi<sup>1,2\*</sup>

Correction: Mol Cancer 19, 92 (2020) https://doi.org/10.1186/s12943-020-01213-6

Following publication of the original article [1], the authors would like to correct an error in Fig. 7d (CD4 and CD8 staining in Hep1-6-Snail tumors treated by PBS, PD1 abs and Sitagliptin. The other Figures of the

article remain the same, and the interpretation of the results remains unchanged. The correction does not affect the conclusion or discussion of this article. The correct and incorrect figures are given below.

<sup>†</sup>Xiao-Yong Huang, Peng-Fei Zhang, Chuan-Yuan Wei, Rui Peng, Jia-Cheng Lu contributed equally to this work.

The original article can be found online at https://doi.org/10.1186/s12943-020-01213-6.

\*Correspondence:

ke.aiwu@zs-hospital.sh.cn

Jian Zhou

zhou.jian@zs-hospital.sh.cn

Guo-Ming Shi

shi.guoming@zs-hospital.sh.cn

<sup>1</sup> Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, 180 Fenglin Road, Shanghai 200032, P.R. China

<sup>2</sup> Cancer Center, Institutes of Biomedical Sciences, Fudan University, Shanghai 200031, P.R. China

<sup>3</sup> State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China


<sup>4</sup> Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital, Fudan University, Shanghai, China




© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Huang et al. Molecular Cancer (2024) 23:44 Page 2 of 4

## Incorrect Fig. 7:



Huang et al. Molecular Cancer (2024) 23:44 Page 3 of 4



**Fig. 7** Sitagliptin improves the response to anti-PD1 immunotherapy in a subgroup of HCC **a**. Schematic of sitagliptin and anti-PD1 treatments; **b**. Representative images of Hep1–6 tumors from each group; **c**. Tumor growth curves of Hep1–6 tumors from each group; **d**. CD4 and CD8 immunohistochemistry staining of tumors treated with PBS, sitagliptin or anti-PD1 antibody. Left, representative pictures of IHC staining. Right, statistic of CD4<sup>+</sup> and CD8<sup>+</sup>T cells per section (n = 3); **e**. DPP4 activities in tumors treated with PBS, sitagliptin or/and anti-PD1 antibody; **f**. CD8 immunohistochemistry staining of HCC from patients with diabetes treated with or without sitagliptin. Left, representative pictures of CD8 IHC staining. Right, statistic of CD8<sup>+</sup>T cells per patient.

Huang et al. Molecular Cancer (2024) 23:44 Page 4 of 4

Published online: 29 February 2024

## Reference

 Huang XY, Zhang PF, Wei CY, et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer. 2020;19:92. https://doi. org/10.1186/s12943-020-01213-6.